BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 12061890)

  • 1. Structurally simple trichostatin A-like straight chain hydroxamates as potent histone deacetylase inhibitors.
    Woo SH; Frechette S; Abou Khalil E; Bouchain G; Vaisburg A; Bernstein N; Moradei O; Leit S; Allan M; Fournel M; Trachy-Bourget MC; Li Z; Besterman JM; Delorme D
    J Med Chem; 2002 Jun; 45(13):2877-85. PubMed ID: 12061890
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel hydroxamate and anilide derivatives as potent histone deacetylase inhibitors: synthesis and antiproliferative evaluation.
    Bouchain G; Delorme D
    Curr Med Chem; 2003 Nov; 10(22):2359-72. PubMed ID: 14529479
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibitors of human histone deacetylase: synthesis and enzyme and cellular activity of straight chain hydroxamates.
    Remiszewski SW; Sambucetti LC; Atadja P; Bair KW; Cornell WD; Green MA; Howell KL; Jung M; Kwon P; Trogani N; Walker H
    J Med Chem; 2002 Feb; 45(4):753-7. PubMed ID: 11831887
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxamates.
    Suzuki T; Nagano Y; Kouketsu A; Matsuura A; Maruyama S; Kurotaki M; Nakagawa H; Miyata N
    J Med Chem; 2005 Feb; 48(4):1019-32. PubMed ID: 15715470
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Simple inhibitors of histone deacetylase activity that combine features of short-chain fatty acid and hydroxamic acid inhibitors.
    Tischler JL; Abuaita B; Cuthpert SC; Fage C; Murphy K; Saxe A; Furr EB; Hedrick J; Meyers J; Snare D; Zand AR
    J Enzyme Inhib Med Chem; 2008 Aug; 23(4):549-55. PubMed ID: 18608778
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of potential antitumor agents. Synthesis and biological evaluation of a new set of sulfonamide derivatives as histone deacetylase inhibitors.
    Bouchain G; Leit S; Frechette S; Khalil EA; Lavoie R; Moradei O; Woo SH; Fournel M; Yan PT; Kalita A; Trachy-Bourget MC; Beaulieu C; Li Z; Robert MF; MacLeod AR; Besterman JM; Delorme D
    J Med Chem; 2003 Feb; 46(5):820-30. PubMed ID: 12593661
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design and synthesis of non-hydroxamate histone deacetylase inhibitors: identification of a selective histone acetylating agent.
    Suzuki T; Matsuura A; Kouketsu A; Hisakawa S; Nakagawa H; Miyata N
    Bioorg Med Chem; 2005 Jul; 13(13):4332-42. PubMed ID: 15927839
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Butyrate and trichostatin A effects on the proliferation/differentiation of human intestinal epithelial cells: induction of cyclin D3 and p21 expression.
    Siavoshian S; Segain JP; Kornprobst M; Bonnet C; Cherbut C; Galmiche JP; Blottière HM
    Gut; 2000 Apr; 46(4):507-14. PubMed ID: 10716680
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis, potency, and cytoselectivity of anticancer agents derived by parallel synthesis from alpha-aminosuberic acid.
    Kahnberg P; Lucke AJ; Glenn MP; Boyle GM; Tyndall JD; Parsons PG; Fairlie DP
    J Med Chem; 2006 Dec; 49(26):7611-22. PubMed ID: 17181145
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alkyl-substituted polyaminohydroxamic acids: a novel class of targeted histone deacetylase inhibitors.
    Varghese S; Gupta D; Baran T; Jiemjit A; Gore SD; Casero RA; Woster PM
    J Med Chem; 2005 Oct; 48(20):6350-65. PubMed ID: 16190761
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis of rigid trichostatin A analogs as HDAC inhibitors.
    Charrier C; Bertrand P; Gesson JP; Roche J
    Bioorg Med Chem Lett; 2006 Oct; 16(20):5339-44. PubMed ID: 16904890
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oestrogen receptor alpha increases p21(WAF1/CIP1) gene expression and the antiproliferative activity of histone deacetylase inhibitors in human breast cancer cells.
    Margueron R; Licznar A; Lazennec G; Vignon F; Cavaillès V
    J Endocrinol; 2003 Oct; 179(1):41-53. PubMed ID: 14529564
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis, and evaluation of isoindolinone-hydroxamic acid derivatives as histone deacetylase (HDAC) inhibitors.
    Lee S; Shinji C; Ogura K; Shimizu M; Maeda S; Sato M; Yoshida M; Hashimoto Y; Miyachi H
    Bioorg Med Chem Lett; 2007 Sep; 17(17):4895-900. PubMed ID: 17588744
    [TBL] [Abstract][Full Text] [Related]  

  • 14. N-alkyl-hydroxybenzoyl anilide hydroxamates as dual inhibitors of HDAC and HSP90, downregulating IFN-γ induced PD-L1 expression.
    Mehndiratta S; Lin MH; Wu YW; Chen CH; Wu TY; Chuang KH; Chao MW; Chen YY; Pan SL; Chen MC; Liou JP
    Eur J Med Chem; 2020 Jan; 185():111725. PubMed ID: 31655430
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of transformed cell growth and induction of cellular differentiation by pyroxamide, an inhibitor of histone deacetylase.
    Butler LM; Webb Y; Agus DB; Higgins B; Tolentino TR; Kutko MC; LaQuaglia MP; Drobnjak M; Cordon-Cardo C; Scher HI; Breslow R; Richon VM; Rifkind RA; Marks PA
    Clin Cancer Res; 2001 Apr; 7(4):962-70. PubMed ID: 11309347
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis and preliminary biological evaluation of new hydroxamate histone deacetylase inhibitors as potential antileukemic agents.
    Guandalini L; Cellai C; Laurenzana A; Scapecchi S; Paoletti F; Romanelli MN
    Bioorg Med Chem Lett; 2008 Sep; 18(18):5071-4. PubMed ID: 18723349
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The discovery of NVP-LAQ824: from concept to clinic.
    Remiszewski SW
    Curr Med Chem; 2003 Nov; 10(22):2393-402. PubMed ID: 14529481
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 2-aroylindoles and 2-aroylbenzofurans with N-hydroxyacrylamide substructures as a novel series of rationally designed histone deacetylase inhibitors.
    Mahboobi S; Sellmer A; Höcher H; Garhammer C; Pongratz H; Maier T; Ciossek T; Beckers T
    J Med Chem; 2007 Sep; 50(18):4405-18. PubMed ID: 17691763
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histone deacetylase inhibitors: the Abbott experience.
    Curtin M; Glaser K
    Curr Med Chem; 2003 Nov; 10(22):2373-92. PubMed ID: 14529480
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Binding mode analysis of 3-(4-benzoyl-1-methyl-1H-2-pyrrolyl)-N-hydroxy-2-propenamide: a new synthetic histone deacetylase inhibitor inducing histone hyperacetylation, growth inhibition, and terminal cell differentiation.
    Mai A; Massa S; Ragno R; Esposito M; Sbardella G; Nocca G; Scatena R; Jesacher F; Loidl P; Brosch G
    J Med Chem; 2002 Apr; 45(9):1778-84. PubMed ID: 11960489
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.